- Home
- MYND vs TVGN Comparison
MYND vs TVGN Comparison
Compare MYND & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYND | TVGN |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Blank Checks |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 21.3M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYND | TVGN |
|---|---|---|
| Price | $0.24 | $6.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 204.0K | 4.9K |
| Earning Date | 08-27-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.00 | $0.14 |
| 52 Week High | $0.72 | $32.90 |
Technical Indicators
Market Signals| Indicator | MYND | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 44.94 |
| Support Level | N/A | $6.15 |
| Resistance Level | $0.35 | $7.65 |
| Average True Range (ATR) | 0.06 | 0.49 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 65.43 | 41.53 |
Price Performance
Historical ComparisonAbout MYND Mynd.ai Inc.
Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.